Detalles de la búsqueda
1.
Risk factors for damage accrual in primary antiphospholipid syndrome: A retrospective single-center cohort study.
J Autoimmun
; 144: 103180, 2024 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38368768
2.
Antiphospholipid antibody carriers and patients with quiescent antiphospholipid syndrome show persistent subclinical complement activation.
Rheumatology (Oxford)
; 2023 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37774001
3.
Predictors of disease activity in gout: a 12-month analysis of the ATTACk (Achieving improvement in the management of crystal-induced arthritis) multicentre cohort study.
Clin Exp Rheumatol
; 41(3): 628-633, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35930471
4.
Impact of COVID-19 and COVID-19 vaccination on high-risk patients with antiphospholipid syndrome: a nationwide survey.
Rheumatology (Oxford)
; 61(SI2): SI136-SI142, 2022 06 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35412604
5.
High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets.
Clin Exp Rheumatol
; 40(11): 2088-2096, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35238757
6.
The first thrombotic event in purely obstetric antiphospholipid syndrome patients and in antiphospholipid antibody carriers: comparison of incidence and characteristics.
Arch Gynecol Obstet
; 303(2): 455-461, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32880711
7.
Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report.
J Autoimmun
; 93: 124-130, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30146007
8.
Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome.
Blood
; 137(21): 2989-2992, 2021 05 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33649771
9.
Detection of autoantibodies to the p200-epitope of SSA/Ro52 antigen. A comparison of two laboratory assays.
Clin Chem Lab Med
; 56(6): 927-932, 2018 05 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-29303768
10.
Plasmapheresis, intravenous immunoglobulins and bethametasone - a combined protocol to treat autoimmune congenital heart block: a prospective cohort study.
Clin Exp Rheumatol
; 34(4): 706-13, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27385463
11.
The efficacy of adalimumab in psoriatic arthritis concomitant to overlapping primary biliary cholangitis and primary sclerosing cholangitis: a case report.
BMC Musculoskelet Disord
; 17(1): 485, 2016 11 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-27876037
12.
Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block.
Transfus Apher Sci
; 53(3): 269-78, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26626966
13.
Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study.
RMD Open
; 10(2)2024 Apr 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38663885
14.
Prevalence and adverse consequences of delayed diagnosis and misdiagnosis in thrombotic antiphospholipid syndrome. An observational cohort study and a review of the literature.
Clin Rheumatol
; 42(11): 3007-3019, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37453028
15.
Short and long-term outcomes of children with autoimmune congenital heart block treated with a combined maternal-neonatal therapy. A comparison study.
J Perinatol
; 42(9): 1161-1168, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35717457
16.
Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study.
Ann Rheum Dis
; 70(6): 1083-6, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21285115
17.
The efficacy and safety of second-line treatments of refractory and/or high risk pregnant antiphospholipid syndrome patients. A systematic literature review analyzing 313 pregnancies.
Semin Arthritis Rheum
; 51(1): 28-35, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33360227
18.
Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study.
Clin Rheumatol
; 40(11): 4569-4580, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34136971
19.
Low Preconception Complement Levels Are Associated with Adverse Pregnancy Outcomes in a Multicenter Study of 260 Pregnancies in 197 Women with Antiphospholipid Syndrome or Carriers of Antiphospholipid Antibodies.
Biomedicines
; 9(6)2021 Jun 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34208130
20.
Upgrading Therapy Strategy Improves Pregnancy Outcome in Antiphospholipid Syndrome: A Cohort Management Study.
Thromb Haemost
; 120(1): 36-43, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31634958